Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

TD Cowen lowered the firm’s price target on BioNTech (BNTX) to $122 from $132 and keeps a Hold rating on the shares. The firm noted ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Welcome to BioNTech’s Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor ...

BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 ...

BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November ...

German biotech BioNTech saw its shares rise more than 3% to $114.98 pre-market today, as it reported financial results for the three months ended September 30, 2024, that beat expectations. Revenues ...

As declining COVID-19 vaccine sales continue to hurt BioNTech’s top line, investors will be keen to get an update on BNTX’s revenue guidance for 2024 on the upcoming conference call.

BioNTech SE (NASDAQ:BNTX) has been notified by its partner, OncoC4 Inc., that the FDA has imposed a partial clinical hold on ...